Chongqing Huasen Pharmaceutical Co., Ltd. announced that its product Penehyclidine Hydrochloride Injection has been proposed for selection in the 12th National Drug Centralized Procurement, with a specification of 1ml:1mg and a proposed selection price of 3.57 yuan per unit. The procurement period runs from the implementation date of the selection results until December 31, 2029. This product is a selective anticholinergic drug, primarily used for pre-anesthetic medication and emergency treatment of organophosphate poisoning. It is an integrated API and formulation product of the company, which passed the consistency evaluation in January 2024. Data from Yaozhiwang shows that hospital-end sales in 2025 remained stable at 602 million yuan. The company stated that this proposed selection is conducive to enhancing brand influence and will have a positive impact on future development. However, the procurement agreement has not yet been signed, and there are still uncertainties in subsequent matters.
Chongqing Pharscin Pharmaceutical Co LtdProduct selected in national procurement, securing hospital sales and enhancing brand influence.